Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

editorial

. 2020 Apr 16;9(8):e016260. doi: 10.1161/JAHA.120.016260

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Mechanism and treatment of atrial fibrillation in hypertrophic cardiomyopathy.A complex interplay of HCM‐related features contributes to development of AF including a postulated primary atrial myopathy. Once AF develops, initiation of anticoagulation is recommended for all HCM patients, regardless of CHA2DS2‐VASc score, and patients should be evaluated for potential non‐HCM contributors to AF including obstructive sleep apnea. A decision for rate vs rhythm control should be made based on degree of symptoms in AF. AF indicates atrial fibrillation; CPAP, continuous positive airway pressure; HCM, hypertrophic cardiomyopathy; and LVOT, left ventricular outflow tract.